Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer

Z Yu, S Chen, AG Sowalsky, OS Voznesensky… - Clinical cancer …, 2014 - AACR
Z Yu, S Chen, AG Sowalsky, OS Voznesensky, EA Mostaghel, PS Nelson, C Cai, SP Balk
Clinical cancer research, 2014AACR
Purpose: Mechanisms mediating androgen receptor (AR) reactivation in prostate cancer that
progresses after castration (castration-resistant prostate cancer; CRPC) and subsequent
treatment with abiraterone (CYP17A1 inhibitor that further suppresses androgen synthesis)
remain unclear. Experimental Design: Prostate cancer xenografts were examined to identify
mechanism of progression after castration and abiraterone. Results: AR reactivation in
abiraterone-resistant VCaP xenografts was not associated with restoration of intratumoral …
Abstract
Purpose: Mechanisms mediating androgen receptor (AR) reactivation in prostate cancer that progresses after castration (castration-resistant prostate cancer; CRPC) and subsequent treatment with abiraterone (CYP17A1 inhibitor that further suppresses androgen synthesis) remain unclear.
Experimental Design: Prostate cancer xenografts were examined to identify mechanism of progression after castration and abiraterone.
Results: AR reactivation in abiraterone-resistant VCaP xenografts was not associated with restoration of intratumoral androgens or alterations in AR coregulators. In contrast, mRNA encoding full-length AR (AR-FL) and a constitutively active splice variant (AR-V7) were increased compared with xenografts before castration, with an increase in AR-V7 relative to AR-FL. This shift toward AR-V7 was due to a feedback mechanism whereby the androgen-liganded AR stimulates expression of proteins that suppress generation of AR-V7 relative to AR-FL transcripts. However, despite the increases in AR-V7 mRNA, it remained a minor transcript (<1%) relative to AR-FL in resistant VCaP xenografts and CRPC clinical samples. AR-V7 protein expression was similarly low relative to AR-FL in castration-resistant VCaP xenografts and androgen-deprived VCaP cells, but the weak basal AR activity in these latter cells was further repressed by AR-V7 siRNA.
Conclusions: AR-V7 at these low levels is not adequate to restore AR activity, but its rapid induction after androgen deprivation allows tumors to retain basal AR activity that may be needed for survival until more potent mechanisms emerge to activate AR. Agents targeting AR splice variants may be most effective when used very early in conjunction with therapies targeting the AR ligand-binding domain. Clin Cancer Res; 20(6); 1590–600. ©2014 AACR.
AACR